Nielsen P E
Center for Biomolecular Recognition, Department for Biochemistry and Genetics, Laboratory B, The Panum Institute, Blegdamsvej 3c, DK-2200 N Copenhagen, Denmark.
Curr Opin Mol Ther. 2000 Jun;2(3):282-7.
Within the past couple of years peptide nucleic acid (PNA) antisense and antigene technology has entered the realm of biological and preclinical studies. This is primarily due to the development of a number of novel methods for more efficient delivery of PNA oligomers to eukaryotic cells. These methods have allowed ex vivo studies on cells in culture to be performed, and parallel in vivo studies are also slowly emerging. Although many issues still need to be resolved and several of the most recent results cannot be rationalized in a straight forward manner by existing knowledge, the immediate future should supply a more solid foundation for assessing the prospects of PNA antisense and antigene technology both in the context of functional genomics and medicine.
在过去几年里，肽核酸（PNA）反义技术和抗原技术已进入生物学和临床前研究领域。这主要归功于一些新方法的开发，这些方法能更有效地将PNA寡聚物递送至真核细胞。这些方法使得在培养细胞上进行体外研究成为可能，同时体内平行研究也在缓慢兴起。尽管仍有许多问题有待解决，且一些最新结果无法用现有知识直接解释，但在不久的将来，对于评估PNA反义技术和抗原技术在功能基因组学及医学背景下的前景，应该会提供一个更坚实的基础。
